Sonnet Biotherapeutics Holdings Inc - Understand $sonn stock

$SONN Market Cap: $2.513 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$55.89K

TTM

Gross Margin

Net Earnings

-$7.985M

TTM

Current Assets

$5.128M

Q2 2024

Current Liabilities

$3.110M

Q2 2024

Current Ratio

164.89%

Q2 2024

Total Assets

$5.797M

Q2 2024

Total Liabilities

$3.179M

Q2 2024

Book Value

$2.618M

Q2 2024

Cash

$3.554M

Q2 2024

P/E

-0.3147

Nov 14, 2024 EST

Free Cash Flow

-$7.093M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue	$100.0K	$349.9K	$483.6K		$30.14M	$30.73M	$41.43M	$41.70M	$35.35M	$29.84M	$8.247M	$6.852M	$1.480M	$140.0K	$600.0K
YoY Change	-71.42%	-27.64%			-1.92%	-25.83%	-0.65%	17.96%	18.47%	261.81%	20.36%	362.99%	957.14%	-76.67%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue	$100.0K	$349.9K	$483.6K	$30.14M	$30.73M	$41.43M	$41.70M	$35.35M	$29.84M	$8.247M	$6.852M	$1.480M	$140.0K	$600.0K
Cost Of Revenue				$28.24M	$28.13M	$37.13M	$36.03M	$31.43M	$27.30M	$7.940M	$6.550M	$1.100M	$0.00
Gross Profit				$1.900M	$2.610M	$4.310M	$5.670M	$3.920M	$2.550M	$310.0K	$310.0K	$370.0K	$140.0K
Gross Profit Margin				6.3%	8.49%	10.4%	13.6%	11.09%	8.55%	3.76%	4.52%	25.0%	100.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Selling, General & Admin	$7.126M	$8.575M	$8.937M	$7.530M	$6.980M	$4.260M	$4.860M	$5.950M	$7.300M	$6.500M	$4.290M	$2.510M	$1.250M	$1.190M	$1.150M
YoY Change	-16.9%	-4.04%	18.68%	7.88%	63.85%	-12.35%	-18.32%	-18.49%	12.31%	51.52%	70.92%	100.8%	5.04%	3.48%
% of Gross Profit					367.37%	163.22%	112.76%	104.94%	186.22%	254.9%	1383.87%	809.68%	337.84%	850.0%
Research & Development	$11.81M	$21.44M		$9.880M
YoY Change	-44.9%
% of Gross Profit
Depreciation & Amortization	$12.85K	$12.85K	$12.46K	$10.00K	$1.840M	$1.820M	$2.280M	$2.340M	$1.700M	$1.590M	$622.3K	$383.5K	$80.00K	$10.00K	$10.00K
YoY Change	0.0%	3.09%	24.6%	-99.46%	1.1%	-20.18%	-2.56%	37.65%	6.92%	155.51%	62.28%	379.32%	700.0%	0.0%
% of Gross Profit					96.84%	69.73%	52.9%	41.27%	43.37%	62.35%	200.73%	123.69%	21.62%	7.14%
Operating Expenses	$18.94M	$30.02M	$0.00	$17.41M	$8.830M	$6.070M	$7.140M	$8.290M	$9.000M	$8.090M	$4.910M	$3.785M	$1.330M	$1.200M	$1.150M
YoY Change	-36.91%		-100.0%	97.17%	45.47%	-14.99%	-13.87%	-7.89%	11.25%	64.78%	29.71%	184.59%	10.83%	4.35%
Operating Profit	-$18.79M	-$29.67M	-$25.09M		-$6.930M	-$3.460M	-$2.830M	-$2.620M	-$5.080M	-$5.540M	-$4.606M	-$2.592M	-$960.0K	-$1.060M
YoY Change	-36.66%	18.26%			100.29%	22.26%	8.02%	-48.43%	-8.3%	20.27%	77.74%	169.96%	-9.43%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Interest Expense	-$40.08K	-$52.48K	-$22.02K	-$30.00K	-$670.0K	-$2.550M	-$2.590M	-$1.120M	-$2.600M	-$660.0K	$757.7K	$474.9K	-$260.0K	-$40.00K	$10.00K
YoY Change	-23.63%	138.33%	-26.6%	-95.52%	-73.73%	-1.54%	131.25%	-56.92%	293.94%	-187.1%	59.55%	-282.66%	550.0%	-500.0%
% of Operating Profit
Other Income/Expense, Net		$0.00	$125.5K		-$620.0K	-$150.0K	$110.0K	-$410.0K	$100.0K		-$680.7K	-$489.7K	-$50.00K	$70.00K	-$280.0K
YoY Change		-100.0%			313.33%	-236.36%	-126.83%	-510.0%			39.01%	879.41%	-171.43%	-125.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Pretax Income	-$18.83M	-$29.72M	-$24.98M	-$24.27M	-$17.37M	-$8.070M	-$7.810M	-$4.150M	-$7.890M	-$6.200M	-$5.287M	-$3.147M	-$1.260M	-$1.030M	-$810.0K
YoY Change	-36.64%	18.96%	2.94%	39.72%	115.24%	3.33%	88.19%	-47.4%	27.26%	17.27%	67.99%	149.79%	22.33%	27.16%
Income Tax					$70.00K	-$700.0K	-$5.480M	$200.0K	$190.0K	-$480.0K	$40.94K	$19.21K	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$18.83M	-$29.72M	-$24.98M	-$24.27M	-$17.73M	-$6.850M	-$6.790M	-$9.080M	-$12.14M	-$6.400M	-$5.214M	-$3.167M	-$1.160M	-$1.010M	-$810.0K
YoY Change	-36.64%	18.96%	2.94%	36.89%	158.83%	0.88%	-25.22%	-25.21%	89.69%	22.74%	64.66%	172.98%	14.85%	24.69%
Net Earnings / Revenue	-18832.69%	-8493.34%	-5165.92%		-58.83%	-22.29%	-16.39%	-21.77%	-34.34%	-21.45%	-63.22%	-46.21%	-78.38%	-721.43%	-135.0%
Basic Earnings Per Share	-$18.14	-$6.84	-$14.25
Diluted Earnings Per Share	-$18.14	-$6.835M	-$1.018M	-$2.576M	-$65.67M	-$48.93M	-$67.90M	-$113.5M	-$242.8M	-$320.0M	-$260.5M	-$317.0M	-$116.0M	-$101.0M	-$81.00M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Cash & Short-Term Investments	$2.274M	$3.053M	$27.62M	$7.350M	$500.0K	$520.0K	$270.0K	$270.0K	$1.530M	$250.0K	$440.0K	$1.220M	$170.0K	$50.00K	$0.00
YoY Change	-25.5%	-88.95%	275.81%	1370.0%	-3.85%	92.59%	0.0%	-82.35%	512.0%	-43.18%	-63.93%	617.65%	240.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$1.677M	$2.361M	$1.189M	$290.0K	$250.0K	$160.0K	$590.0K	$460.0K	$640.0K	$330.0K	$500.0K	$210.0K	$140.0K	$20.00K	$30.00K
YoY Change	-28.96%	98.5%	310.16%	16.0%	56.25%	-72.88%	28.26%	-28.13%	93.94%	-34.0%	138.1%	50.0%	600.0%	-33.33%
Inventory					$290.0K	$340.0K	$460.0K	$540.0K	$730.0K	$530.0K	$380.0K	$230.0K	$110.0K	$0.00
Prepaid Expenses
Receivables					$130.0K	$330.0K	$480.0K	$520.0K	$880.0K	$280.0K	$230.0K	$160.0K	$110.0K	$0.00	$0.00
Other Receivables					$0.00	$0.00	$0.00	$0.00	$50.00K	$80.00K	$160.0K	$200.0K	$120.0K	$90.00K	$30.00K
Total Short-Term Assets	$4.738M	$5.414M	$28.81M	$7.640M	$1.170M	$1.340M	$1.800M	$1.790M	$3.820M	$1.470M	$1.710M	$2.030M	$640.0K	$160.0K	$60.00K
YoY Change	-12.48%	-81.21%	277.11%	552.99%	-12.69%	-25.56%	0.56%	-53.14%	159.86%	-14.04%	-15.76%	217.19%	300.0%	166.67%
Property, Plant & Equipment	$227.1K	$302.8K	$182.3K	$270.0K	$17.30M	$9.760M	$8.550M	$11.51M	$16.64M	$13.32M	$5.620M	$2.320M	$1.510M	$30.00K	$30.00K
YoY Change	-25.02%	66.13%	-32.49%	-98.44%	77.25%	14.15%	-25.72%	-30.83%	24.92%	137.01%	142.24%	53.64%	4933.33%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments					$690.0K	$1.190M	$1.290M	$1.240M	$1.760M	$1.990M	$2.830M	$2.340M	$1.930M	$1.230M	$1.360M
YoY Change					-42.02%	-7.75%	4.03%	-29.55%	-11.56%	-29.68%	20.94%	21.24%	56.91%	-9.56%
Other Assets	$464.2K	$113.3K	$0.00	$80.00K	$150.0K	$2.470M
YoY Change	309.77%		-100.0%	-46.67%	-93.93%
Total Long-Term Assets	$691.3K	$416.1K	$182.3K	$350.0K	$30.36M	$28.45M	$28.38M	$31.70M	$38.39M	$34.32M	$18.38M	$5.620M	$4.160M	$1.250M	$1.390M
YoY Change	66.13%	128.28%	-47.92%	-98.85%	6.71%	0.25%	-10.47%	-17.43%	11.86%	86.72%	227.05%	35.1%	232.8%	-10.07%
Total Assets	$5.429M	$5.830M	$28.99M	$7.990M	$31.53M	$29.79M	$30.18M	$33.49M	$42.21M	$35.79M	$20.09M	$7.650M	$4.800M	$1.410M	$1.450M
YoY Change
Accounts Payable	$2.202M	$4.752M	$3.781M	$2.060M	$4.230M	$6.180M	$5.970M	$5.550M	$5.510M	$5.580M	$2.420M	$1.110M	$480.0K	$210.0K	$190.0K
YoY Change	-53.66%	25.68%	83.56%	-51.3%	-31.55%	3.52%	7.57%	0.73%	-1.25%	130.58%	118.02%	131.25%	128.57%	10.53%
Accrued Expenses	$3.304M	$3.245M	$2.405M	$2.150M	$7.240M	$0.00								$70.00K	$0.00
YoY Change	1.81%	34.94%	11.86%	-70.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$750.00	$750.00	$20.00K	$0.00	$3.000M	$3.000M	$0.00	$0.00	$0.00	$0.00	$0.00	$1.630M	$0.00	$0.00
YoY Change	-100.0%	0.0%	-96.25%		-100.0%	0.0%						-100.0%
Long-Term Debt Due					$6.630M	$3.660M	$5.740M	$6.190M	$8.230M	$2.290M	$890.0K	$260.0K	$1.210M	$250.0K	$410.0K
YoY Change					81.15%	-36.24%	-7.27%	-24.79%	259.39%	157.3%	242.31%	-78.51%	384.0%	-39.02%
Total Short-Term Liabilities	$5.525M	$8.165M	$6.703M	$4.720M	$18.10M	$13.03M	$14.91M	$12.11M	$16.18M	$11.41M	$5.530M	$1.770M	$3.720M	$650.0K	$740.0K
YoY Change	-32.34%	21.8%	42.02%	-73.92%	38.91%	-12.61%	23.12%	-25.15%	41.81%	106.33%	212.43%	-52.42%	472.31%	-12.16%
Long-Term Debt	$0.00	$0.00	$0.00	$120.0K	$710.0K	$3.670M	$850.0K	$4.220M	$1.110M	$6.520M	$920.0K	$60.00K	$320.0K	$690.0K	$0.00
YoY Change			-100.0%	-83.1%	-80.65%	331.76%	-79.86%	280.18%	-82.98%	608.7%	1433.33%	-81.25%	-53.62%
Other Long-Term Liabilities	$130.9K	$203.9K	$30.61K	$130.0K	$15.78M	$4.760M	$2.160M	$1.960M	$1.800M	$2.200M	$1.060M	$280.0K	$270.0K
YoY Change	-35.82%	566.15%	-76.45%	-99.18%	231.51%	120.37%	10.2%	8.89%	-18.18%	107.55%	278.57%	3.7%
Total Long-Term Liabilities	$130.9K	$203.9K	$30.61K	$250.0K	$16.49M	$8.430M	$3.010M	$6.180M	$2.910M	$8.720M	$1.980M	$340.0K	$590.0K	$690.0K	$0.00
YoY Change	-35.82%	566.15%	-87.76%	-98.48%	95.61%	180.07%	-51.29%	112.37%	-66.63%	340.4%	482.35%	-42.37%	-14.49%
Total Liabilities	$5.655M	$8.369M	$6.734M	$4.970M	$35.14M	$22.36M	$19.48M	$20.57M	$20.84M	$25.72M	$9.240M	$2.190M	$4.910M	$1.360M	$740.0K
YoY Change	-32.42%	24.28%	35.49%	-85.86%	57.16%	14.78%	-5.3%	-1.3%	-18.97%	178.35%	321.92%	-55.4%	261.03%	83.78%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	1.038M shares	4.348M shares	1.753M shares
Diluted Shares Outstanding	1.038M shares	197.5K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.513 Million

About Sonnet Biotherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-07-27. The firm's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The firm designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Industry: Pharmaceutical Preparations Peers: Benitec Biopharma Inc Cibus Inc CohBar Inc Ensysce Biosciences Inc Exicure Inc Xenetic Biosciences Inc Navidea Biopharmaceuticals Inc Phio Pharmaceuticals Corp Unicycive Therapeutics Inc